New hope for Hard-to-Treat myeloma: targeted drug combo faces off against standard care

NCT ID NCT06868654

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. About 72 participants in China will be randomly assigned to one of the two groups. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (a targeted antibody-drug conjugate)
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong: This is an early-stage Phase 3 trial with only 72 participants in China. The drug may not prove better than the current standard, and side effects like eye problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Beijing, China
GSK Investigational Site

Changchun, China
GSK Investigational Site

Guangzhou, China
GSK Investigational Site

Hangzhou, China
GSK Investigational Site

Jinan, China
GSK Investigational Site

Nanjing, China
GSK Investigational Site

Shenyang, China
GSK Investigational Site

Suzhou, China
GSK Investigational Site

Tianjin, China
GSK Investigational Site

Wuhan, China
GSK Investigational Site

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.